0001140361-23-028021.txt : 20230602 0001140361-23-028021.hdr.sgml : 20230602 20230602160538 ACCESSION NUMBER: 0001140361-23-028021 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230530 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bionano Genomics, Inc. CENTRAL INDEX KEY: 0001411690 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 261756290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38613 FILM NUMBER: 23988660 BUSINESS ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 888-7600 MAIL ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Bionano Genomics, Inc DATE OF NAME CHANGE: 20190308 FORMER COMPANY: FORMER CONFORMED NAME: BioNano Genomics, Inc DATE OF NAME CHANGE: 20120703 FORMER COMPANY: FORMER CONFORMED NAME: BioNanomatrix Inc DATE OF NAME CHANGE: 20070906 8-K 1 brhc20053893_8k.htm 8-K
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2023

Bionano Genomics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware
001-38613
26-1756290
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

9540 Towne Centre Drive, Suite 100
San Diego, California
  
92121
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (858) 888-7600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
BNGO
The Nasdaq Stock Market LLC
Warrants to purchase Common Stock
BNGOW
 The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
 
On May 30, 2023, Bionano Genomics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
 
The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq Capital Market under the symbol “BNGO.”
 
Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days following the date of the Notice to regain compliance with the Minimum Bid Price Requirement. If at any time during this 180 day period the closing bid price of the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Price Requirement and the matter will be closed.
 
If the Company does not regain compliance with the Minimum Bid Price Requirement within the initial 180 day compliance period, the Company may be eligible for an additional 180 calendar days to regain compliance if, on the last day of the initial compliance period, the Company meets the market value of publicly held shares requirement for continued listing as well as all other standards for initial listing of its common stock on The Nasdaq Capital Market (other than the Minimum Bid Price Requirement), and the Company notifies Nasdaq of its intention to cure the deficiency during the second compliance period. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. If the Company does not indicate its intent to cure the deficiency, or if it appears to Nasdaq that it is not possible for the Company to cure the deficiency, the Company will not be eligible for the second compliance period.

If the Company does not regain compliance with the Minimum Bid Price Requirement within the applicable compliance period, the Company’s common stock will be subject to delisting.
 
The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Bionano Genomics, Inc.
     
Date: June 2, 2023
By:
  
/s/ R. Erik Holmlin, Ph.D.
   
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
   


EX-101.SCH 2 bngo-20230530.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 bngo-20230530_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 bngo-20230530_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Common Stock [Member] Class of Stock [Domain] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Warrants to purchase Common Stock [Member] EX-101.PRE 5 bngo-20230530_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 30, 2023
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 30, 2023
Entity File Number 001-38613
Entity Registrant Name Bionano Genomics, Inc.
Entity Central Index Key 0001411690
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-1756290
Entity Address, Address Line One 9540 Towne Centre Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 888-7600
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol BNGO
Security Exchange Name NASDAQ
Warrants to purchase Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Warrants to purchase Common Stock
Trading Symbol BNGOW
Security Exchange Name NASDAQ
XML 7 brhc20053893_8k_htm.xml IDEA: XBRL DOCUMENT 0001411690 2023-05-30 2023-05-30 0001411690 bngo:WarrantsToPurchaseCommonStockMember 2023-05-30 2023-05-30 0001411690 us-gaap:CommonStockMember 2023-05-30 2023-05-30 false 0001411690 8-K 2023-05-30 Bionano Genomics, Inc. DE 001-38613 26-1756290 9540 Towne Centre Drive Suite 100 San Diego CA 92121 858 888-7600 false false false false Common Stock, $0.0001 par value per share BNGO NASDAQ Warrants to purchase Common Stock BNGOW NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 23 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bionanogenomics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc20053893_8k.htm bngo-20230530.xsd bngo-20230530_def.xml bngo-20230530_lab.xml bngo-20230530_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc20053893_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bngo-20230530_def.xml" ] }, "inline": { "local": [ "brhc20053893_8k.htm" ] }, "labelLink": { "local": [ "bngo-20230530_lab.xml" ] }, "presentationLink": { "local": [ "bngo-20230530_pre.xml" ] }, "schema": { "local": [ "bngo-20230530.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bngo", "nsuri": "http://bionanogenomics.com/20230530", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc20053893_8k.htm", "contextRef": "c20230530to20230530", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://bionanogenomics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc20053893_8k.htm", "contextRef": "c20230530to20230530", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bngo_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase Common Stock [Member]" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://bionanogenomics.com/20230530", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001140361-23-028021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-028021-xbrl.zip M4$L#!!0 ( +* PE93]<-0PP, D1 1 8FYG;RTR,#(S,#4S,"YX MT!#1+@GD0!_-X/AML^[ZA MK^5"DA54&"DL"E!_X IDC0FDWDJI>A&&F=: &2^ \8H2&1!>A;-HED3SQ,@J MH0*FWG%1O8$E;DJ5>O\TN*1+"KF'=!Q,+M:RM_;\_!P\)P$7A382Q>'?'QX^ M6_\.F[&"7^B[)924?=TQO\Y$Z1PDH=G.L(1>RP&^DQ/?W-R$=K>':D/TC&G* MI,*,P!"?JYXP!,_#=M-!4+7FW MHM?,B2[<+3S"$MDS7AB#J2=I59?F .W:2L R]4P&^.Z6O]0" JW0000OXO8F<""'%@YR %MA-<@%-51;U,H_&YAY; <&Y:F4$;_ST&5 M.!L;E*9 ^6/C,7:>= 3(#/Y\O#];7:RH-YPTIJK]QO*W3%&UN=<9+2J;4!ZB M>>J=1?3^G8+MS=U%NNA%$?*1LS <8I:CUAP:V+L-]XWLVV\DY!_9G1WO)W_' M[B#GF 27I"FO(.XFYG%>M^KNPA6,<*]BM N[=<54%9UZ7"C$#OY.PZ)68%QW M-:W]ISUP8LVT:.EJ[5%."*62;L6F=+"6N M;HU<\T4,GPJCSLCAV_,Q#XU11W/JB7*U]ZG7<_0]=DK,?S'M7.X+Z5[<5DGJ M_86%P$S))_ZI$62E&^#?>55Q]EEQ\O4#5!F(MF,UG?J7B]!MM]\_/!M.Z*]%H.-9HH5/,S5NL M;MLISY]:5XWH6FL3I6T!VR.[^Q=02P,$% @ LH#"5BKE@(+L!@ T40 M !4 !B;F=O+3(P,C,P-3,P7V1E9BYX;6S5G%USXC84AN\[T_] Z;5Q@-(V MF65WTFS289K=, F=;7N3$;8 S=H2(XD-^?>5C)58LN0/(%YSDQ#KY>B\>B0C M'^R\^["-H\XW2!DB>-SM]\ZZ'8@#$B*\''?+M$<)?+^2/.6"P M([K%[&++T+B[XGQ]X?M/3T^]IV&/T*4_.#OK^_]\NGT(5C &'L*, QS ;D?H M+UAR\)8$@"7G?7(P8P&0),8E1P'H!B7VI\3^28!-#S"]Q>(TYXL\3O" T3H98])\$ MY<]K..XR%*\CJ(ZM*%R,NW.\)&+X!L.ST?!,#M[/Q?'\3*J !BK;]&4VX1>C M"',_1+&?:GP01>5Y.896C9@D/DK23:(=(2OQ&F*YE+P0+L FXD?,T1+[N!F3 M&* *L/=). U]C'R34%X,XSFDQTQ6CWN$3%RVM!25P^MJ30PFN:%QU'I XG M'3T"H2&DZ:[D[=E(A,5^1@A4D"#9@"IR3&% M%!%Q$@H_BJVH8Q59-<9R,C3M!5?%5,T%9H1*00Z;!7F#6 "B?R&@-^*(>3(O M41DPV%5@N7PATU W>7 MXXVXPO^\R0Z,MNO*-VO;K6QS>PF66*D(+A\EY?5KD[SNX5(D1P'FGT%L?DX6 M231NIJ3M[ HMU>)G1DH9_M8DPRNQ_"F()N)R;?L7?+9"=&@TBCE-VS$6FZK% M,1DP ]M)*.8E6J!=';O@@[5$JTT!I[;M\*N9K(7=&5*5%[@%.F:Y@ZD M.WBEVU#)R97)L"+=846ZPU.D:YH[D.[PE6Y#=2@MDROQ\H[.R!,N8IM7VT&56*D(*Q]% 6NHA/0 @PT5V?4'\YG,W #F:DY= MYIO;"ZS$2D5@^2CJOH6&*D S"N0-M0_/\9Q$!BUK6^K/:&LOIR(3%2$9(12A MAJHXGXG6O^4.H )%:M2J:"^S!BN E]#RC6>1Q#@U MZI+V(JQ@J>8I4H^D(#9:CKF.(5V*!/^DY(FOKDB\!MA^45>HU"X%',KVDJUN ML-;%@".@XMQ0B>:+F&D<8M%]O,'I=S/F?4*%FM2Z0]->JE5,5>3I"*5(-E1_ M>2 1"I#,[A/@D")@[F[< G7*M0C:"[#43M73K26.0M=0U65*H9P\$ %: M/A% [Q:+W/5?N3#U7B1L+]+*]BJB+8JG$#=4=3%2F3"V@;0R:*?J5QG8)ZK%10HM V4H7A+LIDG^VINEXILU-HF&8$4M:2\ MP_L70408#,==3C=P=X!@#K?\.DJXC[L,+N6+PQ$O )LG@[1AWA* ]8XSC#A3 M1UZ!IP<>D^]D9/=7$6#L;O' 2?#UOP J;_!G,S+=T& % M&"R#5.,=JDQ1Y1VM!%G?:SG:2C'S*_6=;PR,V+9]E?]69'=<_I#_AN/]_U!+ M P04 " "R@,)6X12C3!$* 0:@ %0 &)N9V\M,C R,S U,S!?;&%B M+GAM;,V=76_;.!:&[P>8_\#QWLP"XSBVT042-!YDTW80;)H$308SNX-!(=[S\NLYHJW8ZOM?M^L8?< Y'09I&$6#7V<__O#^I^'P-YQ@&F1X@>:OZ-^4! L:+588 MW7^Y6T8Q1I/IR;N3\CD=_?KYY")_P.AA&29H%28@'B.G/T[SQAH1!EH^Y MDKZ=TU@83$>[OHP*_J^AD UYTW \&4[')]MT,2B'R,,.G0CY5M.7>=1D>"L.TR/)@MC/.',_ M?:Q:-\T'?>MK:6U#OO6YRJS(<0>K7.FF^:#O,8W(XF.R:'_@:E>^!O^0!;0# M5/3.FD^@_5$#0XUYTPW[2>H7;S.<+/!"],R]+=?.O.O\8IL[[[Q)*+G&_!0A M5)].REQSQV60SG-;=A:N@F##["?3$8ZS5+0,>4L^I[+AZQ59KTGRD)'PVV>\ MGN.=?SZUBX$QGD49GQ40'\G3X#[21"A.R3,-L=*3<41?XWE\T%)*)!3#K#-? MQVP8_&4$3H:_/PQ0M*C+F17-*&]'?Q61O]^/]E/2E^&2REL:T%",D_U8,[=2 M,0H).VY\C38HR@FI\1L> . [2]&Z9C^4#60=1 MHE)L% B, 4%3CC5+KR";W*TDPTFSO!V1I8"YB!T;9O.>$==55G#6M!+/!J=C M ,V.Q@RO<9)5!W6YC5*%M5I=N0 674/*C.#'[]II(# MUU\N V-*M1IJ?)L618K#DQ7Y/EK@J*@']L.^#-@_V/'"WNE?SM.,!F&FO2@! M8KL7)%+LC7AK(_"!L\D4PA?6SO(F1FG9>.Q+-+@/I&;YU-<8%1DGT)#;/G$? M2/C,B7]DC@H.4*BZ55-.RZ!IP!_HZ M$F[F)2'/.K PA.79< M1NV[1AP76:86E M\+5[M<_Q XBB,LBA9?68O%&@4Q I29H%X30H(&N"KV_EB MU^AL M>0,-NW(Q$X\BM-\QX1EU557E=J6D&JR:5]3.\IYO6!V1+D5WI^7X[> M+9?:?:YZ83E9F[ !OF9;7QC7]F#"N29QQN+#L") A0+EDN,"[K"KY)#UEX$W MYPCPZUP[+X#K-'W&U+D,C'*X& "YOY+0S%LJ#%,_CN4!I^M%4NCZ6ROFK8!=(S>+)5$HR@2"0V]V-B$]1&@;Q?W% /[$6]5UBC4JY/:&I/-RI M4#Q]W[2 [>ON7T!9^UL9113Q,,KC_;BO8=I#XKS@\-T.)4&]\0'Z=L(!'<6U'<[U#MQ(5_,TU@M!_VB']A/DW;#T-N(K*3#SFF=WU.\^ MN_.!O1*U8\-(BOV9O)[7_P*XBO02/QJVD: ZPX M^B48-KL%* M(EJ6OY6TX%FCE5@U:AN#:W#V2[&]$SO2MES!-],@6=0CVNOVF1RX'5 =&-+D MHK!Z=U4AUTE(Z(;0? #Y1^VNR#,[0UZOR )^*>V4(55+34;CFK'Z^ZT()?2@H-R#(FW8,*BYKLEQB#OUT56@?UYBNHF3U M&R4OV=,566^"!'ZQ;U5*A650-BXHT-=O(=FZL!>0.5,4CE"@0H)*31]JQ;ZW MY*!-@&H#3))KPN+;52U<+A:,P;3\ZR9*\!BL!(M.J@-0U[@* %>_-6#NP%X! MICS!?QGX1?R N 3=);TX+6Q[2@Y8?HA^($5FW^AY//(GCN1/',F?M$+^I&WR M)V\D?^) _N,+Z2?Y$U?R)X>3/ZDC?W)L\J>.Y$\=R9^V0OZT;?*G;R1_ZD(^ MV[">7O6GKNQ/#V=_6L?^]"CL7[$?[^@C>5&_%%RC@KBOJGQ1O_=LA7G-WHEX M)4OCG&[5SN)6^W:WTE1;_0%\$>X:WN&'B!UU?8=G4O;^V"E_:J M4\?XWI,T"^+_11OC;P5L0@AE1>@+:,FV%:RA'IS@UA,UQ L)8IK>W-RW[BL$ MO'$'+-A+.2#\@&L'#W[@_5,< -!#H7*"^J![&I_YH$IG^4MM MWM0#.L$-(/:%DPFLJG9/>] RVZ>,/Y,SOG\B"?S9&5.XG(P>;D"<:N:+.H.O MB3Q0/LM;4=[&U"^F3**J%#3"#ET=_3=1RK\GG3X&\Q@^\T&%=-@K MBL:GO.3G]WB'K.WGNIXA#G0107_EL2,_&\>V6<1I=:&C6Q++9S;@TS6T_";? M=8;7ZA=Y:E0@O!65-X!WGNU K-J[@2QGZ3#S.,H%O2):WT60:G#);63O$F"Z M%;\.'G2"PV?*!C">S!_YL!7(3.%RBGJXR2-.%#-O#SB!?8V/-X'DL_Q'_B"] M\>3G^3^1$!WY 2>FW2'U*RI#JBIWCS8!'=K'\I8\TH _^?[A=3TG,?#-=(NB MG!JH:, GX.<+4;.UB5)3QNR6H#*"BE /OK]NVROBM+@RK8!8 &OT:9]9J6.% M'S!63DJ)-2!4[H_K@-G]AF M8.![BC:)-70]U$.>-<=YUK*3$20"/7@>XK6#2-N"PR?[%6U>KKK M3F^@=YZL2 [HZ;OI:0XI;_GZ1T#Y5R#31W+/@'D*4ESW3/X#,LJI.F6\$6G7 M2?!U&S=E_-#.(.@/\Y@))6=B4VI1#Q_^?P@5Y(W;)E>.0S9?M -[*O]_CR;)B<_%A MG2;!=T@9(OBRU>V+6;G M:X8N6XLL6YZ'X>/C8^>QWR%T'O9.3KKA/U^N[Z,%3$$;898!',%6P/'G+#]X M32*0Y3'OG+Z>TD01],-M7Y4(\5=;P=KB4+O;:_>[G36+6S)$T>S0B8*O2WBI MJ7MV=A;FK5LH)T(6ZJULGKT@V.2/D@3>P5D@?O]]-ZH\^RP4B!##[!I,8<*[ MS$_/GI;PLL50NDR@.K:@<&;F22C=THCLG(GL=-^)[/SZS!SN$]Y/ND&H4S[; TSF$),41:P3D733PT<2K5*(LP'FUV?Y*'9^79#75+(.#!ON>8'"IW!=09Q#&/5G8AU M3S%YUZKSA$2%_A)Q122T7!K&^\OKPF#4F9/O80Q1*!2+#[GT7#;_XV%(^%)@ M,&49!5&FF!)1H\N6L8U'*%1I;>&K![K)S35B&5^HL F8/I=5AFM!R*"-B'U# MGP$VS0< 7SO- 5ANXH=)QM219R'RP ,?M!D411\F@+';V7U&HF^#-6*:I%J< M%&;!_0AYNU%\)"E 6'=6)4#9RP#X(4I(FA*MD[$;0:GF$%*Y37 HB47DNQ>*!I5O3S!BR,/7P&E &=L0L8K&BWX M$KZNN@W.D%ER.L-3!S17Z^())U;IDNZ!7/*&*:V?H8G#=%=,9"5G/L8,7 <> M9&^8/MLUF[A?_XKY,Y"*S%G(?L0LM=?ZAZ\]X8BKT1<,-2CC.F@']?HRU&IW MPAFUV$U-,N!BDR=N+6>76$783+KE$D8M/6B-$&L(;QN>(NLAH/:8U,.J!W! ZX M0BP"R;\0T"M^1+_NU* T%Y10Q^ #N[3&3BC122_TC\8+&R_7N\& ,_JA@#L> M1U3+>Z$G"H32%;]Y[(J-L"N4P)N5X2:ZJKFP%MUM]KGT-6*<*U[FD84^];[0 M=W".Q+8OSFY :MZ#-4,*!=&]CR9@/8JY;C1#F^=Z+(N'&FS!.Y58_UWC)K.A M7RI)I5/.O'?*((ZY9"9_"8E=HTLLN()#C#C_W5$OKZ$SC(1J3\KG[<:J\'N. MMN@YVJ)WG+;0Y>UMB]ZS+7S>JZP*O^]HB[ZC+?K':0M=WMZVZ#_;PN<-S$+X M0_[QED[(H_Y$2@W*9(E=U-$8HE+:R^RP2Z?,X/,.9B'X?/5\2\>4?$>;A\TK M'5$!-=FB!#T:;]A%OLP@)4[E$O]W-)7%-[=7UOFB"#%.%@IR-&XPBWKA-*&X M5/7]W^:4D8\)RT#R'UI6;F_8@"8G:,"C\8--X,M-X<3"L0KK?=/ MZ90D6IF-;3(M6IO/!;;)<*ZN1J*>2/)Y_^^&%((V/'1H0DG/) MC52J\#[O\*F9Z-,Z6@ \AX8'$&P0;18O0GRNO8.HQK-YD4M5W_^-O$\II'.N MZC,EC]EB2-(EP.:;5^SJ#6+Q?M,+R MOYWZHXE6C,Q8!<9G.[C(Z"*)'X_ D/53&!F.3L#%+"U6_?+ MEBS)B@F5P$",/JG3^^?+YB S&DK?OXX/1\UK&.C=,I&BM0F266 MH;NK%EM 5!VR-)\"AS0+%" \!&##G(YZMVQ ':D'*Q1_?+C\/ //%\//0#MY M2N,L3-(AS642XVQ:2S-:NE$;I)4)UA@(OK?[RM/J6C M^466#8V%.D+^)D" MJLV2H@#7;U,H.RU47 M;9C/LU6')Q>1[*2!##;-MMO6WKME'KWTM&DU3V M!SD!#&W2(KB6>O=6JT)H*')*<&4M\==8WKS;Z25Q#E.WKD%H=@@KOKW;R<5= MWE$K)1WH>]@IEPH?@X1/2)9/(O%N)P3X5DB',IITR;^NY5!DY$SK? 1+]D,L;(OF[G>.KBX\2E?T7R;F(=RJ,N,Q&$05LXB06T.50WG41=Y$6 M'Q6T^@@ 9T#V5#(2TR%V%;+['OC D1[R2Q1(5@E3GLS$JK!'[W; AG5#>2MP--LFUN6 MYJ_'] CXH%NZ[OC:'%:=)@U3$0JT42([.D27ULV4LX*AB7)QW4&*LZ#RM:KQ MVW<9WRF;T52]V\GDISJ*]9,D[5-^7"N^5R% 46+J>$$XIP MU3?)\7LH14K4?&*A3^F=_MHDQ_W.1]6CYN@CH%;"JV_@N-/\[")%J:7;+ MG XU:YNBR9> 5BW5]VJ23H,.&Y+ESZLS/WVD* M_C//KI,+(/0 @II>,APFL8+X(H:!2+=-U)(VHH\(%E\Y3'8WBB23>8$#X6!N MX@Q,^;N=TFUWERYJYPAEL+O!T@X["V>;DGF*U(_'^!^!S17(C\373M/L=6HN MK0/^4+EE\.WX\3 ;T?BQWGGGB!QV<(#FN(.T&C!(4IBU]*VD^-8*DCQ/AC#$ MZ(YD220Y"2+PX=/V/!EUB76_<2 P8%$3W\V"@-+3KP@"&A$$!%:Y2 _(D*9] M&;5[TG1JY/>;Y>GUZD=_[ER^G5U>GYV1N9-T?> M6(;\[S0;0':2)_$^.6[WVI!LV);_4DB[AK+D)9#66X;\Q_/++V1IX%]EB46F M-HWW':;Y-C5=VW4TB]F"4LX]6_?A?UOGF'BLC?>]UJ_S@?X;/Y^,/-BCRY.S M:W)Y?U2L'H-UFD"O!L+Q'=),D*='M7;Y'DI#D _%2 ML'W5I ;RCE.92^A[<@>Y4MP7Y#W+D<2Z;UHO!ZZ]W#A4HB3HK4HN8GJ.X'KA[Z@>D**]#

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